About Akorn
Akorn is a Healthcare company based in Lake (United States) founded in 1948, and was acquired by Biological E in August 2020. Injectable and ophthalmic pharmaceutical products were manufactured across therapeutic areas. It operates on a Reseller / Distribution model. The company has 1,367 employees. Akorn has completed 3 acquisitions, including Hi-Tech, Thera Tears and VersaPharm. Akorn offers products and services including Buprenorphine, Naloxone, Phenylephrine, Albuterol Sulfate Inhalation Solution, and Anased (Xylazine) Injection. Its focus areas include Pharmaceuticals and Generic Drugs. Its legal entity is Akorn Operating Company LLC.
Company details
Akorn Operating Company LLC was engaged in the distribution of pharmaceutical products, including generics and veterinary solutions. Operations covered a range of medications such as Buprenorphine, Naloxone, and Albuterol Sulfate Inhalation Solution. The company served the healthcare sector with a focus on human and animal health. In February 2023, it filed for Chapter 7 bankruptcy and ceased all operations.
- Headquarters Lake, United States
- Employees 1,367
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website akorn.com
- Social LinkedIn
- Acquired by Biological E (Aug 2020)
- Legal Name Akorn Operating Company Llc
- Annual Revenue$682.43 M (USD)-2as on Dec 31, 2019
- Net Profit-$226.77 M (USD)44as on Dec 31, 2019
- EBITDA-$188.06 M (USD)52as on Dec 31, 2019
- Latest Funding Round$120M (USD), Post-IPO
May 2011
- InvestorsBiological E
& 1 more
- Employee Count1,367
- Investments & AcquisitionsHi-Tech
& 2 more
- Acquired by
Products & Services of Akorn
Akorn offers a comprehensive portfolio of products and services, including Buprenorphine, Naloxone, Phenylephrine, Albuterol Sulfate Inhalation Solution, and Anased (Xylazine) Injection.
Buprenorphine is provided for opioid dependency treatment solutions.
Naloxone is offered for reversing opioid overdose effects.
Phenylephrine is supplied for nasal congestion relief purposes.
Albuterol is delivered for asthma and respiratory conditions.
Xylazine is used for sedation in veterinary applications.
Funding Insights of Akorn
- Total Rounds 1
- Last Round Post-IPO — $120M
- First Round $120M
(May 2011)
All 1 funding rounds of Akorn with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2011 | $120M | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in Akorn
Akorn has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Biological E and Fresenius Kabi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Vaccines and therapeutics for multiple diseases are developed and marketed. | 1953 | biologicale.com | Hyderabad, India | |
Healthcare solutions in pharmaceuticals, nutrition, MedTech, and biopharmaceuticals. | 1999 | fresenius-kabi.com |
Investor details for Akorn
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Akorn
89 people are tracked at Akorn (17 in leadership, 72 in team); the tracked headcount is 1,367.
| Name | Role | Group |
|---|---|---|
Damanjit Singh | Vice President & General Manager | Leadership |
Colleen Cooke | Senior Director Human Resources | Leadership |
Jonathan Kafer | Chief Commercial Officer | Leadership |
Ron Bruns | Executive Director / General Manager Branded Ophthalmics Division | Leadership |
Mark Kepchar | Executive Director Of Field Sales | Leadership |
Christopher C. Young | Executive Vice President, Global Operations | Leadership |
Katrin Hitz | Head Of Human Resources Akorn AG | Leadership |
Erislandy Dorado-Boladeres | Executive Vice President, Global Quality | Leadership |
Ajai Saxena | Head Of Environment, Health, And Safety | Leadership |
Mark Silverberg | Executive VP Operations Global Assurance Technical Services | Leadership |
Steve Brodner | Director Of Planning | Leadership |
Demba Sowe | Director Financial Reporting | Leadership |
Mark Ganan | Vice President Internal Audit | Leadership |
Scott Tranter | Director National Accounts | Leadership |
Kamran Jameel | Director Of FP A And Accounting | Leadership |
Kaustubh Gavaskar | Executive Director, Quality | Leadership |
Diane Davis | Sales Director | Leadership |
Carina Kress | Manager Production Planning | Team |
Katrin Schmidt | Administrator Bulk Production | Team |
Shashikant Bhardwaj | Engineer | Team |
69 more people are available in the full profile.
Complete people profiles for Akorn
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Akorn
Akorn has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Hi-Tech, Thera Tears and VersaPharm.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Generic pharmaceuticals are developed and marketed in key categories. | versapharm.com | Marietta, United States | 1995 | May 2014 | $440M | |
Generic, branded, and OTC pharmaceutical products are manufactured. | hitechpharm.com | Amityville, United States | 1983 | Aug 2013 | $640M | |
Eye drops are manufactured by Thera Tears for therapeutic purposes. | theratears.com | Ann Arbor, United States | 1997 | Mar 2011 | $26M |
Complete acquisition details for Akorn
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Akorn
8 dated milestones of Akorn across 72 years, from founding to its latest funding, stage changes and deals.
- Founded Akorn is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Thera Tears.
- Funding First funding round of $120.0M.
- Acquisition Acquires Hi-Tech.
- Acquisition Acquires VersaPharm.
- Exit Acquired by Fresenius Kabi.
- Exit Acquired by Biological E.
Web traffic of Akorn
Websites that share an audience with Akorn (akorn.com).
- Global rank#11,843,991
among all websites
- Category rank#8,174
Health · Biotechnology and Pharmaceuticals
- Bounce rate49%
- Pages per visit1.6
- Average visit35 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with Akorn. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sagentpharma.com | 100% | 16.1K | #1,111,836 | View details | |
| impaxlabs.com | 99% | View details | |||
| pfizer.com | 91% | 1.9M | #24,984 | View details | |
| santen.com | 78% | 305.6K | #167,724 | View details | |
| oraclinical.com | 78% | 8.4K | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 28 similar websites and full traffic analytics for Akorn
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 28 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Akorn (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | USD 3.02 B | 8,300 | ||
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | USD 5.1 B | 13,500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Akorn
Complete news archive for Akorn
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Akorn
Akorn was founded in 1948 and raised its 1st funding round 63 years after it was founded.
Akorn is headquartered in Lake, United States.
Akorn has 1,367 employees.
Annual revenue of Akorn is $682.43M as on Dec 31, 2019.
Akorn Operating Company LLC was engaged in the distribution of pharmaceutical products, including generics and veterinary solutions. Operations covered a range of medications such as Buprenorphine, Naloxone, and Albuterol Sulfate Inhalation Solution. The company served the healthcare sector with a focus on human and animal health. In February 2023, it filed for Chapter 7 bankruptcy and ceased all operations.
Akorn offers Buprenorphine, Naloxone, Phenylephrine, Albuterol Sulfate Inhalation Solution, and Anased (Xylazine) Injection.
Akorn has made 3 acquisitions, including Hi-Tech, Thera Tears, and VersaPharm.
Akorn has 2 investors. Key investors include Biological E, and Fresenius Kabi.
Akorn operates through Akorn Operating Company Llc.
Yes. Akorn was acquired by Biological E in August 2020.